Environmental, genetic, and molecular features of prostate cancer

被引:53
作者
Deutsch, E
Maggiorella, L
Eschwege, P
Bourhis, J
Soria, JC
Abdulkarim, B
机构
[1] Inst Gustave Roussy, UPRES, Lab EA 27 10, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Radiat Therapy, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[4] Univ Paris 11, Dept Urol, Le Kremlin Bicetre, France
[5] Univ Alberta, Cross Canc Inst, Dept Radiat Oncol, Edmonton, AB, Canada
关键词
D O I
10.1016/S1470-2045(04)01468-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is the sixth most common cancer in the world and the third leading cause of cancer in men. The increase in the understanding of prostate carcinogenesis over the past 15 years has helped to define crucial steps in the natural history of the disease, namely initiation and progression to androgen independence. This heterogeneous disease encompasses a range of environmental and familial factors, which provides strong support for the use of chemopreventive strategies. Most patients with advanced prostate cancer are treated with androgen-deprivation therapy, which leads to a striking regression of androgen-responsive cancer cells. A transition from an androgen-responsive to an androgen-unresponsive stage is seen during the clinical course in almost all patients with prostate cancer. This transition also signals a substantial worsening of prognosis. Here, we review the most important findings in prostate carcinogenesis and the molecular anomalies associated with the androgen-refractory stage.
引用
收藏
页码:303 / 313
页数:11
相关论文
共 87 条
[21]  
Erdamar S, 1999, MODERN PATHOL, V12, P751
[22]  
Fenton MA, 1997, CLIN CANCER RES, V3, P1383
[23]  
Fernández PL, 1999, J PATHOL, V187, P563, DOI 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO
[24]  
2-3
[25]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[26]   Cellular and molecular pathology of prostate cancer precursors [J].
Foster, CS ;
Bostwick, DG ;
Bonkhoff, H ;
Damber, JE ;
van der Kwast, T ;
Montironi, R ;
Sakr, WA .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 :19-43
[27]  
Gayther SA, 2000, CANCER RES, V60, P4513
[28]   Body mass index and risk of prostate cancer in US health professionals [J].
Giovannucci, E ;
Rimm, EB ;
Liu, Y ;
Leitzmann, M ;
Wu, K ;
Stampfer, MJ ;
Willett, WC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (16) :1240-1244
[29]  
Giovannucci E, 2002, JNCI-J NATL CANCER I, V94, P391, DOI 10.1093/jnci/94.5.391
[30]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33